Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa: NIMH Project Accept (HPTN 043)

JM. Fogel, W. Clarke, M. Kulich, E. Piwowar-Manning, A. Breaud, MT. Olson, MA. Marzinke, O. Laeyendecker, A. Fiamma, D. Donnell, JK. Mbwambo, L. Richter, G. Gray, M. Sweat, TJ. Coates, SH. Eshleman,

. 2017 ; 74 (2) : 158-165.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023515

BACKGROUND: Antiretroviral (ARV) drug treatment benefits the treated individual and can prevent HIV transmission. We assessed ARV drug use in a community-randomized trial that evaluated the impact of behavioral interventions on HIV incidence. METHODS: Samples were collected in a cross-sectional survey after a 3-year intervention period. ARV drug testing was performed using samples from HIV-infected adults at 4 study sites (Zimbabwe; Tanzania; KwaZulu-Natal and Soweto, South Africa; survey period 2009-2011) using an assay that detects 20 ARV drugs (6 nucleoside/nucleotide reverse transcriptase inhibitors, 3 nonnucleoside reverse transcriptase inhibitors, and 9 protease inhibitors; maraviroc; raltegravir). RESULTS: ARV drugs were detected in 2011 (27.4%) of 7347 samples; 88.1% had 1 nonnucleoside reverse transcriptase inhibitors ± 1-2 nucleoside/nucleotide reverse transcriptase inhibitors. ARV drug detection was associated with sex (women>men), pregnancy, older age (>24 years), and study site (P < 0.0001 for all 4 variables). ARV drugs were also more frequently detected in adults who were widowed (P = 0.006) or unemployed (P = 0.02). ARV drug use was more frequent in intervention versus control communities early in the survey (P = 0.01), with a significant increase in control (P = 0.004) but not in intervention communities during the survey period. In KwaZulu-Natal, a 1% increase in ARV drug use was associated with a 0.14% absolute decrease in HIV incidence (P = 0.018). CONCLUSIONS: This study used an objective, biomedical approach to assess ARV drug use on a population level. This analysis identified factors associated with ARV drug use and provided information on ARV drug use over time. ARV drug use was associated with lower HIV incidence at 1 study site.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023515
003      
CZ-PrNML
005      
20170908095819.0
007      
ta
008      
170720s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/QAI.0000000000001229 $2 doi
035    __
$a (PubMed)27828875
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fogel, Jessica M $u *Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; †Department of Probability and Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic; ‡Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD; §Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; ‖Program in Global Health, University of California at Los Angeles, Los Angeles, CA; ¶Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; #Department of Global Health, University of Washington, Seattle, WA; **Muhimbili University of Health and Allied Sciences, Muhimbili University Teaching Hospital, Dar es Salaam, Tanzania; ††DST-NRF Centre of Excellence in Human Development, University of the Witwatersrand, Johannesburg, South Africa; ‡‡Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa; §§South African Medical Research Council, Cape Town, South Africa; ‖‖Department of Psychiatry and Behavioral Sciences, The Medical University of South Carolina, Charleston, SC; and ¶¶Center for World Health, David Geffen School of Medicine and UCLA Health, Los Angeles, CA.
245    10
$a Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa: NIMH Project Accept (HPTN 043) / $c JM. Fogel, W. Clarke, M. Kulich, E. Piwowar-Manning, A. Breaud, MT. Olson, MA. Marzinke, O. Laeyendecker, A. Fiamma, D. Donnell, JK. Mbwambo, L. Richter, G. Gray, M. Sweat, TJ. Coates, SH. Eshleman,
520    9_
$a BACKGROUND: Antiretroviral (ARV) drug treatment benefits the treated individual and can prevent HIV transmission. We assessed ARV drug use in a community-randomized trial that evaluated the impact of behavioral interventions on HIV incidence. METHODS: Samples were collected in a cross-sectional survey after a 3-year intervention period. ARV drug testing was performed using samples from HIV-infected adults at 4 study sites (Zimbabwe; Tanzania; KwaZulu-Natal and Soweto, South Africa; survey period 2009-2011) using an assay that detects 20 ARV drugs (6 nucleoside/nucleotide reverse transcriptase inhibitors, 3 nonnucleoside reverse transcriptase inhibitors, and 9 protease inhibitors; maraviroc; raltegravir). RESULTS: ARV drugs were detected in 2011 (27.4%) of 7347 samples; 88.1% had 1 nonnucleoside reverse transcriptase inhibitors ± 1-2 nucleoside/nucleotide reverse transcriptase inhibitors. ARV drug detection was associated with sex (women>men), pregnancy, older age (>24 years), and study site (P < 0.0001 for all 4 variables). ARV drugs were also more frequently detected in adults who were widowed (P = 0.006) or unemployed (P = 0.02). ARV drug use was more frequent in intervention versus control communities early in the survey (P = 0.01), with a significant increase in control (P = 0.004) but not in intervention communities during the survey period. In KwaZulu-Natal, a 1% increase in ARV drug use was associated with a 0.14% absolute decrease in HIV incidence (P = 0.018). CONCLUSIONS: This study used an objective, biomedical approach to assess ARV drug use on a population level. This analysis identified factors associated with ARV drug use and provided information on ARV drug use over time. ARV drug use was associated with lower HIV incidence at 1 study site.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a Afrika $7 D000349
650    _2
$a antiretrovirové látky $x terapeutické užití $7 D044966
650    _2
$a průřezové studie $7 D003430
650    12
$a spotřeba léčiv $7 D004363
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HIV infekce $x farmakoterapie $x prevence a kontrola $7 D015658
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a Národní institut pro duševní zdraví (USA) $7 D009315
650    _2
$a těhotenství $7 D011247
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a Spojené státy americké $7 D014481
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Clarke, William
700    1_
$a Kulich, Michal
700    1_
$a Piwowar-Manning, Estelle
700    1_
$a Breaud, Autumn
700    1_
$a Olson, Matthew T
700    1_
$a Marzinke, Mark A
700    1_
$a Laeyendecker, Oliver
700    1_
$a Fiamma, Agnès
700    1_
$a Donnell, Deborah
700    1_
$a Mbwambo, Jessie K K
700    1_
$a Richter, Linda
700    1_
$a Gray, Glenda
700    1_
$a Sweat, Michael
700    1_
$a Coates, Thomas J
700    1_
$a Eshleman, Susan H
773    0_
$w MED00005434 $t Journal of acquired immune deficiency syndromes (1999) $x 1944-7884 $g Roč. 74, č. 2 (2017), s. 158-165
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27828875 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170908100420 $b ABA008
999    __
$a ok $b bmc $g 1239196 $s 984428
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 74 $c 2 $d 158-165 $i 1944-7884 $m Journal of acquired immune deficiency syndromes $n J Acquir Immune Defic Syndr $x MED00005434
LZP    __
$a Pubmed-20170720
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace